Tag: intellia
November 13, 2018
CRISPR Trials to Watch in 2018
CRISPR Cas-9 gene editing is finally in clinical studies. Here's an overview of CRISPR genetics testing trials currently in progress. March 14, 2018
Intellia Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results
Intellia Therapeutics (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR technology, announced financial results and...
March 8, 2018
4 Gene Editing Technologies Explained
We look at four types of gene editing currently in clinical trials, as well as the pros and cons of... February 27, 2018
Intellia Therapeutics Announces Publication in Cell Reports of Preclinical Data Demonstrating Effective CRISPR/Cas9 Genome Editing
Intellia Therapeutics (NASDAQ:NTLA), a leading genome editing company developing curative therapeutics using CRISPR/Cas9 technology, announced that Cell Reports will publish at noon...
October 5, 2017
4 Gene Therapy Stocks to Watch in 2017
At the halfway mark of 2017, here's a look at how these four gene therapy companies are performing so far... August 1, 2017
Intellia Therapeutics Posts Q2 Financial Report
Intellia Therapeutics released its financial results for the second quarter of 2017.
March 9, 2017